Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Mateos MV et al. Blood. 2014 Aug 7. pii: blood-2014-05-573733. [Epub ahead of print].
Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplant.
Freytes CO et al. Biol Blood Marrow Transplant. 2014 Aug 16. pii: S1083-8791(14)00506-0. doi: 10.1016/j.bbmt.2014.08.007. [Epub ahead of print].
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
Cheng J et al. Transfusion. 2014 Aug 13. doi: 10.1111/trf.12813. [Epub ahead of print].
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH et al. Vox Sang. 2014 Jul 31. doi: 10.1111/vox.12183. [Epub ahead of print].
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma.
Popat R et al. Br J Haematol. 2014 Aug 8. doi: 10.1111/bjh.13072. [Epub ahead of print].
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Wang TF et al. Bone Marrow Transplant. 2014 Jul 28. doi: 10.1038/bmt.2014.163. [Epub ahead of print].
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Reece DE et al. Br J Haematol. 2014 Aug 22. doi: 10.1111/bjh.13100. [Epub ahead of print].
Phase II study of pomalidomide in high risk relapsed and refractory multiple myeloma.
Usmani SZ et al. Leukemia. 2014 Aug 25. doi: 10.1038/leu.2014.248. [Epub ahead of print]